Investor interest in antibody‑drug conjugates accelerated this week as Tubulis closed a $361 million Series C to advance its clinical ADC pipeline, and Adcytherix announced a €105 million (US$122 million) Series A to move its lead ADC program toward IND-enabling studies. Both financings underscore renewed capital availability for targeted-delivery oncology platforms after a period of quieter markets. Tubulis said the round—one of the largest private ADC financings to date—will fund pivotal-enabling studies and manufacturing scale-up; Adcytherix will push its lead candidate into the clinic next year. Venture participation included life‑science specialist funds and strategic investors. The closings reflect a sectorwide recalibration: investors are backing differentiated linker‑payload chemistry and targeting strategies that promise improved therapeutic windows and address past ADC safety or efficacy limitations.